财务表现 - 2023年第四季度营收为1,510万美元，同比增长9%[1] - 2023年全年营收为6,820万美元，同比增长20%[1] - 2023年全年净利润为2,060万美元，同比增长44%[1] - 固定费用软件许可收入为3,730万美元，同比增长9%[2] - 变动费用软件许可收入为2,900万美元，同比增长36%[3] - 其他产品销售额为190万美元，同比增长42%[4] - 成本费用为700万美元，同比增长64%[5] - 总营业费用为4,590万美元，同比增长16%[6] - 净利润为2,060万美元，同比增长44%[9] 公司业务 - Semler Scientific, Inc. 开发、制造和营销创新产品和服务，帮助评估和治疗慢性疾病[30] - QuantaFlo® 是 Semler Scientific 的旗舰产品，通过快速的现场测试来测量四肢的动脉血流[30] - QuantaFlo® 用于帮助诊断心血管疾病，如外周动脉疾病（PAD），Semler Scientific 正在寻求扩大适应症的新 510(k) 许可[30] - Semler Scientific 在 Mellitus、SYNAPS Dx 和 Monarch Medical Technologies LLC 中有少数投资[30] 前瞻性声明 - Semler Scientific 的前瞻性声明包括寻求 QuantaFlo® 新的 510(k) 许可以扩大使用范围[31] - Semler Scientific 的前瞻性声明受到多种风险和不确定性的影响，可能导致实际结果与讨论的结果有所不同[32] - Semler Scientific 的前瞻性声明涉及假设、估计和不确定性，反映了当前的内部预测、期望或信念[32] - Semler Scientific 不保证这些声明将被证明准确，实际结果和未来事件可能与这些声明中预期的有重大差异[32] - Semler Scientific 假设没有义务更新或修订这些声明，除非法律另有要求[32]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (St ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Doug Murphy-Chutorian – Chief Executive Officer Renae Cormier – Chief Financial Officer Jennifer Oliva Herrington – Chief Operating Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Herbert Semler – Semler Health Operator Good afternoon, and welcome to the Semler Scientific 2023 Third Quarter Financial Results Conference Call. All participants will be in a lis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State o ...

Start Time: 16:30 January 1, 0000 4:49 PM ET Semler Scientific, Inc. (NASDAQ:SMLR) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO Renae Cormier - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today’s presentation, there ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State o ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Douglas Murphy-Chutorian - Interim Chief Executive Officer Renae Cormier - Head of Corporate Communications and Business Strategy Andrew Weinstein - Senior Vice President, Finance and Accounting Dennis Rosenberg - Chief Marketing Officer Conference Call Participants Operator Good afternoon, and welcome to the Semler Scientific 2023 First Quarter Financial Results Conference Call. All participa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State or other ju ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2022 Results Conference Call March 21, 2023 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary Wayne Pan - New CEO Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Dennis Rosenberg - Chief Marketing Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2022 Fourth Quarter and Full Yea ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary Dennis Rosenberg - Chief Marketing Officer Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marc Wiesenberger - B. Riley Securities Operator Hello and welcome to the Semler Scientific Third Quarter 2022 ...